What we do
Genetic Technologies may have a long history in delivering the most timely and accurate laboratory results and analysis, but it's our connection with our customers that sets us apart.

Our customers have real health concerns so keeping them waiting for a 'test result' or 'analysis' simply doesn't make any sense. They rightly demand to know what is going on.

We typically lead the market in the quickest turnaround times for the tests we conduct.

In many cases, those turnaround times are months ahead of sizeable public institutions. Such is our success over many years, that we find ourselves driving the entire market to reduce waiting times and still deliver accurate results. Which means we just keeping working harder to maintain our competitive advantage.

Building a reputation for test and analysis excellence means building a brand that speaks to industry leading performance. And because we service such important and diverse markets across both animal and human areas, we are building a brand portfolio that each customer can readily relate to, knowing that each comes from a single high-quality heritage.

1. Developing a cancer management suite

In 2010, we will be expanding on our traditional markets and entering ones that are related to our core business.

Whilst we dominate the private breast cancer screening sector, new tests will be added through the in-licensing of products from leading companies to target cancer management. These new tests cover the latest developmental areas from diagnosis through staging, therapy and into surveillance; particularly in the five years following treatment.

These tests aim to give the clinician more precise information as to the nature and extent of the cancer resulting in more targeted and therefore effective courses of treatment. The outcomes for the patient range from less chance of inefficient treatment regimes to higher probabilities of quality of life extension, not to mention the reduction in health care costs for the community.

The key cancers to be targeted are breast, lung, prostate and colorectal. By working with Oncologists and Pathologists we are confident that we can add test regimes beyond screening and into diagnosis, through to staging and post operative care.

2. Creating a ‘super clinic’ in specialised Animal Veterinary Care

Whilst we have an extensive range of DNA disease and trait tests for companion animals, the acquisition of ‘Frozen Puppies’ has enabled us to devise a strategy to become the specialist centre for genetic and fertility management. Aimed at both vets and pedigree breeders, the ‘Animal Genetic & Fertility Network’ provides expertise for maximising breeding outcomes. From semen collection and freezing, to insemination and conception, through the life and health management of a dog with disease and trait testing, the Animal Network is a complete expert centre.

Specialised groups within animal populations that are in danger of becoming inbred can also utilise the Animal Network in order to ascertain and get advice on maximising the breed’s genetic diversity.

The Company's clinics and operations continue to expand both in Australia and through China and Japan. Specially designated ‘Hubs’ in the USA also provide for semen collection and transportation to anywhere in the world. Pedigree breeders can access each other’s details through our web based Stud Register and, providing we collect and inseminate the semen, they can use our ‘Puppy Guarantee’. For the first time, breeders have a complete service, available from a number of locations, that covers all aspects of their breeding programs.

3. Personal DNA – uncovering how your DNA affects your lifestyle

As the community becomes more familiar with the role that DNA plays in disease identification and management, its role in everyday lifestyle is now being more closely examined.

Having already launched the ACTN3 Sports Gene Test®, we will be expanding into the area of ‘individual tolerances’ to provide customers with more information about how particular lifestyle issues are connected to their DNA make-up.

Areas under development range from auto-immune conditions such as lactose intolerance to daily health conditions such as blood pressure. By empowering people with more information as to the composition of their DNA, they can better understand if a particular condition is more likely to be affected by hereditary or environmental factors. Knowing this will mean they can access different treatment regimes. In some cases this information will also provide clinicians with a clearer picture of the condition in conjunction with the current set of tests they utilise.

These tests will be accessed from both direct marketing through the internet as well as selective healthcare channels, giving people the opportunity to build up a picture of their DNA make-up based on specific health issues. In an era of instantaneous information gathering and sorting, the intention is not to replace the clinical evaluation and diagnostic process but to empower people through greater knowledge tailored to their individual genetic make-up.

4. Using our IP to create relationships in expanding markets

Traditionally, we have focused on the Australian market for increasing our operational revenue base, but in 2009 we formalised our expansion into the broader Asian market.

By utilising our IP and test development abilities, we launched our canine genetic and fertility management operations in China and set up genetic management activities in Japan.

In the New Zealand market we began selling both human and animal services to mirror those being offered in Australia and we continue to bring in more commercial revenue from relationships in the ASEAN region; primarily through Malaysia, Singapore and Indonesia. Preliminary relationships continue to grow in Korea and Thailand where alliances are being sought.

By building a presence across Asia, enhanced by senior relationships at both a public and private level, we plan to introduce broader elements to our product and services portfolio.

The portfolio of products and services will be tailored to the market developmental needs of each country in which we operate. This will allow us to help create the genetic and fertility dynamics of each market and in doing so capture a ‘first mover’ advantage, delivering a long term dominant market position.

5. We’re becoming a company focused on sales and marketing, founded on testing

Clearly, with an emphasis on successful commercial realisation, a move to higher levels of customer focus and insight are key to expanding our business in 2010 and beyond.

Deliberate engagement with our key customers will enable us to develop a ‘closer to market’ point of view, which we aim to then translate into profitable products and value added services. This is especially important with the genetic markets as they are complex, fast changing and cut across many traditional forms of health management.

Our goal is to create solutions to our customer’s unmet needs, delivering results that are superior in both time and cost to our competitors, such that we are viewed by our customers as the ‘partner of choice’.

We know many customers are both conservative in nature and new to the implications of genetic management. That is why it is vital we bring our expertise in creating a position as ‘knowledge guardians’; providing the right information and solutions at the time they need it most.

This will be translated into building a sales and marketing team that looks beyond just selling another test or service to one that sees the solution to the problem and is able to articulate a mutually beneficial point of view.